We had an awesome dinner meeting with VTGN and its CEO last night. Several of the physicians attending brought up the benefits of the compound would have with the NFL and concussions.
While Depression is one blockbuster indication pain therapy is also a blockbuster indication.
The 1.8 billion allergan deal for an intravenous therapy and the success Alchemy had even after 2 phase 3 trials failed have paved the way. VTGN is using the same randomization method that Alchemy used when they had success and their market cap skyrocketed 2.8 billion in one day.
Allergan deal happened after Phase 2 and Alchemy after Phase 3.
to believe fast track designation will be obtained this year and are hoping US patents are approved this year. EU patents were approved earlier this year.
The Alchemy model puts the market in the US alone at over 5bil in sales yearly. This would be as an injunctive treatment. Currently most old class drugs are cheap and will be first line even with all the bad side effects, but with 3 out of 4 patients failing to get positive results out of first line the adjunctive model has a big marketplace.
Approval as an adjunctive (or add on ) provides an easier path to FDA approval.
Pretty exciting that a biotech with this low of a marketcap could have definitive NIH results by 2018 Q1 and Phase 2 adjunctive by Q4 2018 or early 2019.
The stem cell therapy company is very exciting as well, and while not definite has a possibility of being spun off as a new company which shareholders would get a dividend share in the new company. This is not definite, and was only broached as a topic of discussion because several physicians at the dinner were very interested in that company. It does not have blockbuster potential IMO but the Japanese marketplace is very interested in this. They are in a partnership with milestones with a BAYER subsidiary.
Very interesting though.
]
News 
Market Data 
Discover 
